Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep 27;88(6):799-802.
doi: 10.1097/TP.0b013e3181b4aaf5.

Kidney after nonrenal transplantation-the impact of alemtuzumab induction

Ron Shapiro  1 , Amit Basu, Henkie P Tan, Claire Morgan, Vivek Sharma, Deanna Blisard, Parmjeet S Randhawa, Igor Dvorchik, Jerry McCauley, Demetrius Ellis, J Wallis Marsh, Steven Webber, Geoffrey Kurland, Kenneth R McCurry, Kareem Abu-Elmagd, George Mazariegos, Thomas E Starzl
Affiliations

Kidney after nonrenal transplantation-the impact of alemtuzumab induction

Ron Shapiro et al. Transplantation. .

Abstract

Background: Calcineurin inhibitor nephrotoxicity in nonrenal allograft recipients can lead to end-stage renal disease and the need for kidney transplantation. We sought to evaluate the role of alemtuzumab induction in this population.

Patients and methods: We evaluated 144 patients undergoing kidney transplantation after nonrenal transplantation between May 18, 1998, and October 8, 2007. Seventy-two patients transplanted between January 15, 2003, and October 8, 2007, received alemtuzumab induction and continued their pretransplant immunosuppression. Seventy-two patients transplanted between May 18, 1998, and July 21, 2007, did not receive alemtuzumab induction, but received additional steroids and maintenance immunosuppression. Donor and recipient demographics were comparable.

Results: Overall, 1- and 3-year patient survival and renal function were comparable between the two groups. One- and 3-year graft survival was 93.0% and 75.3% in the alemtuzumab group and 83.3% and 68.7% in the no alemtuzumab group, respectively (P=0.051). The incidence of acute rejection was lower in the alemtuzumab group, 15.3%, than in the no alemtuzumab group, 41.7% (P=0.0001). The incidence of delayed graft function was lower in the alemtuzumab group, 9.7%, than in the no alemtuzumab group, 25.0% (P=0.003). The incidence of viral complications was comparable.

Conclusion: Alemtuzumab induction with simple resumption of baseline immunosuppression in patients undergoing kidney transplantation after nonrenal transplantation represents a reasonable immunosuppressive strategy.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Graft survival in kidney transplantation after nonrenal transplantation (alemtuzumab; no alemtuzumab).
See this image and copyright information in PMC

References

    1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:331. - PubMed
    1. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol. 2002;19(suppl):S3. - PubMed
    1. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath lH, and low- dose cyclosporine monotherapy in renal allograft recipients. Lancet. 1998;351:1701. - PubMed
    1. Stuart FP, Leventhal JR, Kaufman DB. Alemtuzumab facilitates prednisone free immunosuppression in kidney transplant recipients with no early rejection. Am J Transplant. 2002;2(suppl):397. - PubMed
    1. Knechtle SJ, Pirsch JD, Fechner HJ, Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation results of a pilot study. Am J Transplant. 2003;3:722. - PubMed

MeSH terms